Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

3(50.0%)

Phase 2

3(50.0%)

6Total

Phase 1(3)

Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05224960Phase 2Recruiting

Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2)

Role: collaborator

NCT05227846Phase 1Unknown

Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-1)

Role: collaborator

NCT05507762Phase 1Unknown

Study of Human Umbilical Cord Mesenchymal Stem Cell in Patients With Cirrhosis Due to Hepatitis B (Compensation Stage)

Role: collaborator

NCT05121870Phase 2Unknown

Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis

Role: collaborator

NCT04288102Phase 2Completed

Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19)

Role: collaborator

NCT04252118Phase 1Unknown

Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19

Role: collaborator

All 6 trials loaded